Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 12, 2026, 1:36 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1873–1896 of 35,388 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: alone Clear all

Conditions: Metastatic Pancreatic Adenocarcinoma
Interventions: PEGPH20, Oxaliplatin, Leucovorin, Irinotecan, 5-fluorouracil; Drug
Lead sponsor: SWOG Cancer Research Network; Network
Eligibility: 18 Years to 75 Years
Enrollment: 126 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2023
U.S. locations: 154
States / cities: Anchorage, Alaska • Tucson, Arizona • Auburn, California + 112 more

Conditions: Healthy
Interventions: AG-920; Drug
Lead sponsor: American Genomics, LLC; Industry
Eligibility: 19 Years and older
Enrollment: 14 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021
U.S. locations: 1
States / cities: Lincoln, Nebraska

Conditions: Chronic Obstructive Pulmonary Disease
Interventions: TRN-157, Placebo; Drug
Lead sponsor: Theron Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014
U.S. locations: 1
States / cities: Cypress, California

Conditions: Pancreas Cancer, Relapse, Resistant Cancer
Interventions: iC9-CAR.B7-H3 T cell infusion; Biological
Lead sponsor: UNC Lineberger Comprehensive Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2030
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Healthy Volunteers
Interventions: LY2452473; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years to 55 Years · Male only
Enrollment: 6 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Heart Failure
Interventions: Adaptive CRT (aCRT), Echo; Device
Lead sponsor: Medtronic Cardiac Rhythm and Heart Failure; Industry
Eligibility: 18 Years and older
Enrollment: 522 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 55
States / cities: Huntsville, Alabama • Anchorage, Alaska • Phoenix, Arizona + 52 more

Conditions: Abdominal Aortic Aneurysm (AAA)
Interventions: Nellix System; Device
Lead sponsor: Endologix; Industry
Eligibility: 18 Years and older
Enrollment: 333 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2022
U.S. locations: 27
States / cities: Tucson, Arizona • San Diego, California • New Haven, Connecticut + 23 more

Conditions: Constipation, Hirschsprung Disease
Interventions: Endoscopic mucosal resection (EMR); Procedure
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 10 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2018
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Bioavailability
Interventions: PF-07321332/ritonavir, PF-07321332; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Diabetic Foot Ulcer
Interventions: Restrata TM Wound Matrix; Device
Lead sponsor: Acera Surgical, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2018
U.S. locations: 5
States / cities: Phoenix, Arizona • Tucson, Arizona • Fresno, California + 1 more

Conditions: Cardiac Surgery, Opioid Use, Unspecified
Interventions: Bupivacaine Injection, Liposomal bupivacaine, Saline; Drug · Other
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 18 Years to 80 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Atrial Fibrillation
Interventions: ECG monitoring with a Kardia Mobile monitor; Other
Lead sponsor: Valley Health System; Other
Eligibility: 18 Years to 100 Years
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 3
States / cities: West Des Moines, Iowa • Paramus, New Jersey • Springfield, Oregon

Conditions: Influenza
Interventions: CSL Limited Influenza Virus Vaccine (Afluria®), US Licensed Influenza Virus Vaccine (Fluzone®); Biological
Lead sponsor: Seqirus; Industry
Eligibility: 65 Years and older
Enrollment: 1,268 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2009
U.S. locations: 13
States / cities: Mountain Home, Arkansas • Boise, Idaho • Iowa City, Iowa + 10 more

Conditions: Healthy, Clostridium Difficile Infection
Interventions: omeprazole; Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 15 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013
U.S. locations: 1
States / cities: Scottsdale, Arizona

Conditions: Melanoma, Ocular, Melanoma, Cutaneous, Metastatic Melanoma, Melanoma, Mucosal, Liver Metastases
Interventions: Ipilimumab, Nivolumab, Stereotactic Body Radiation Therapy; Drug · Procedure
Lead sponsor: University of Michigan Rogel Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Glucose, Low Blood, Glucose, High Blood
Interventions: Dose Safety AP system; Device
Lead sponsor: Dose Safety Inc.; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Redmond, Washington

Conditions: Multiple Sclerosis, Relapsing-Remitting
Interventions: Natalizumab; Drug
Lead sponsor: Biogen; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 585 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2023
U.S. locations: 52
States / cities: Cullman, Alabama • Homewood, Alabama • Irvine, California + 45 more

Conditions: Atrial Arrhythmia
Interventions: Acorys Mapping System; Device
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Dementia With Lewy Bodies
Interventions: Armodafinil; Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 50 Years to 90 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Chronic Kidney Disease (Stages 1-4)
Interventions: CommunityRx-Kidney Health; Behavioral
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 18 Years and older
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026
U.S. locations: 1
States / cities: Beulaville, North Carolina

Conditions: Open-Angle Glaucoma
Interventions: Blood Collection Only; Other
Lead sponsor: Alcon Research; Industry
Eligibility: 18 Years and older
Enrollment: 1,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2008
U.S. locations: 1
States / cities: Fort Worth, Texas

Conditions: Cardiovascular Diseases, Coronary Disease, Heart Failure, Congestive, Heart Diseases
Interventions: CABG surgery plus MED, Active Medication Alone, CABG plus MED and SVR; Procedure · Drug
Lead sponsor: Duke University; Other
Eligibility: 18 Years to 100 Years
Enrollment: 2,136 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2015
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Advanced Solid Tumor, Metastatic Solid Tumor, Soft Tissue Sarcoma (STS), Platinum-resistant Ovarian Cancer (PROC), Hepatocellular Carcinoma (HCC), Colorectal Cancer (CRC), HER2 Negative Breast Cancer, Cutaneous Melanoma, Renal Cell Carcinoma (RCC)
Interventions: GI-102 subcutaneous (SC), GI-102, doxorubicin, paclitaxel, bevacizumab, eribulin, trastuzumab deruxtecan (T-DXd), pembrolizumab; Drug
Lead sponsor: GI Innovation, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 358 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 5
States / cities: Scottsdale, Arizona • Jacksonville, Florida • Rochester, Minnesota + 2 more

Conditions: Alzheimer Disease, Cognition Disorders
Interventions: florbetapir F 18 PET scan; Drug
Lead sponsor: Avid Radiopharmaceuticals; Industry
Eligibility: 50 Years and older
Enrollment: 317 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 75
States / cities: Glendale, Arizona • Phoenix, Arizona • Scottsdale, Arizona + 62 more

Search by objective public record fields.

S1313, PEGPH20 in Treating Patients With Newly Diagnosed Metastatic Pancreatic Cancer

An Open Label, Study of the Systemic Exposure to Articaine After Topical Ocular Dosing of AG-920

Single Ascending Dose Study of TRN-157 in Healthy Subjects

Autologous CAR-T Cells Targeting B7-H3 in PDAC

Disposition of 14C-LY2452473 Following Oral Administration in Healthy Human Subjects

Adaptive Cardiac Resynchronization Therapy Study

Safety and Effectiveness Study of Endovascular Abdominal Aortic Aneurysm Repair Using the Nellix® System

Endoscopic Mucosal Resection for the Diagnosis of a-Ganglionosis, a Controlled Prospective Trial (EDGE Trial)

Relative Bioavailability Study of 4 Different Formulations of PF-07321332 Relative to the Commercial Tablet Formulation

Clinical Outcomes After Treatment With RestrataTM Wound Matrix in Diabetic Foot Ulcers (DFU)

Pecto-Intercostal Fascial Plane Block Study

Cryoballoon vs. Rhythmia Guided Ablation for Recurrent AFib

A Study to Determine the Immunogenicity and Safety Profile of CSL Limited's Influenza Virus Vaccine Compared to a US Licensed Comparator Influenza Virus Vaccine

The Impact of Proton Pump Inhibitors on the Fecal Microbiome

Hepatic Ablation of Melanoma Metastases to Enhance Immunotherapy Response, a Phase I Clinical Trial (HAMMER I)

Dose Safety Hybrid Closed Loop and Fully Automated Closed Loop Artificial Pancreas Device in CRC

A Study to Evaluate Efficacy, Safety, and Tolerability of EID of Natalizumab (BG00002) in Participants With RRMS Switching From Treatment With Natalizumab SID in Relation to Continued SID Treatment- Followed by Extension Study Comprising SC and IV Natalizumab Administration

ACORYS AI4AF PILOT STUDY

"Pilot Study of Armodafinil in Patients With Dementia With Lewy Bodies"

CommunityRx-Kidney Health

Collection of Blood Specimens From Patients in AL-3789 Studies for Elevated Intraocular Pressure (IOP)

Comparison of Surgical and Medical Treatment for Congestive Heart Failure and Coronary Artery Disease

A Study to Evaluate the Safety and Therapeutic Activity of GI-102 As a Single Agent and in Combination with Conventional Anti-cancer Drugs, Pembrolizumab or Trastuzumab Deruxtecan(T-DXd) in Patients with Advanced Solid Tumors (KEYNOTE-G08)

Registry of Amyloid Positive Patients for Alzheimer's Disease Drug Research Trials